These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 12876900)
41. Questions, questions. The future of HIV research. Huff B GMHC Treat Issues; 2005 Dec; 19(12):4-8. PubMed ID: 16909507 [No Abstract] [Full Text] [Related]
42. HIV models to inform health policy. Stover J Curr Opin HIV AIDS; 2011 Mar; 6(2):108-13. PubMed ID: 21505384 [TBL] [Abstract][Full Text] [Related]
43. Key issues for a potential human immunodeficiency virus vaccine. Hu DJ; Vitek CR; Bartholow B; Mastro TD Clin Infect Dis; 2003 Mar; 36(5):638-44. PubMed ID: 12594646 [TBL] [Abstract][Full Text] [Related]
44. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Velasco-Hernandez JX; Gershengorn HB; Blower SM Lancet Infect Dis; 2002 Aug; 2(8):487-93. PubMed ID: 12150848 [TBL] [Abstract][Full Text] [Related]
45. State of the science. HIV vaccine development. Grady C; Kelly G Nurs Clin North Am; 1996 Mar; 31(1):25-39. PubMed ID: 8604385 [TBL] [Abstract][Full Text] [Related]
47. Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. Dimitrov D; Kublin JG; Ramsey S; Corey L EBioMedicine; 2015 Dec; 2(12):2062-9. PubMed ID: 26844286 [TBL] [Abstract][Full Text] [Related]
48. Gulliver's travels in HIVland. Weiss RA Nature; 2001 Apr; 410(6831):963-7. PubMed ID: 11309625 [TBL] [Abstract][Full Text] [Related]
49. No vaccine for 10 years. AIDS Patient Care STDS; 1999 Jun; 13(6):377. PubMed ID: 10842867 [No Abstract] [Full Text] [Related]
50. Curbing the global AIDS epidemic. Gayle HD N Engl J Med; 2003 May; 348(18):1802-5. PubMed ID: 12724488 [No Abstract] [Full Text] [Related]
52. AIDS vaccine 2001: looking to the future. Mitsuyasu RT Afr Health Sci; 2001 Dec; 1(2):99-105. PubMed ID: 12830816 [No Abstract] [Full Text] [Related]
53. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. Blower S; Bodine E; Kahn J; McFarland W AIDS; 2005 Jan; 19(1):1-14. PubMed ID: 15627028 [TBL] [Abstract][Full Text] [Related]
54. Macroeconomic impact of HIV: the need for better modelling. Lamontagne E; Haacker M; Ventelou B; Greener R Curr Opin HIV AIDS; 2010 May; 5(3):249-54. PubMed ID: 20539082 [TBL] [Abstract][Full Text] [Related]
55. Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines? Endsley AN; Salama NN; Ho RJ Curr HIV Res; 2008 Sep; 6(5):401-10. PubMed ID: 18855650 [TBL] [Abstract][Full Text] [Related]
56. Analytic insights into the population level impact of imperfect prophylactic HIV vaccines. Abu-Raddad LJ; Boily MC; Self S; Longini IM J Acquir Immune Defic Syndr; 2007 Aug; 45(4):454-67. PubMed ID: 17554215 [TBL] [Abstract][Full Text] [Related]
57. HIV-1 therapeutic vaccine: a ray of hope. Arora DR; Gautam V; Arora B Indian J Med Microbiol; 2003; 21(4):225-32. PubMed ID: 17643033 [TBL] [Abstract][Full Text] [Related]
58. [Vaccines, molecular scissors, fusion inhibitors. What does HIV therapy of the future look like?]. Warpakowski A MMW Fortschr Med; 2009 Nov; 151(46):22-3. PubMed ID: 20043388 [No Abstract] [Full Text] [Related]
59. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Blower SM; Koelle K; Kirschner DE; Mills J Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3618-23. PubMed ID: 11248127 [TBL] [Abstract][Full Text] [Related]
60. Modelling the impact of acute infection dynamics on the accumulation of HIV-1 mutations. Shiri T; Welte A J Theor Biol; 2011 Jun; 279(1):44-54. PubMed ID: 21420419 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]